

The Drug Utilization Review Board Reviewed the Following New Drugs and Supplemental Rebate Classes on March 15, 2012

The Georgia Medicaid Fee-for-Service Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following new drugs and supplemental rebate classes for the Georgia Medicaid Fee-for-Service Preferred Drug List (PDL).

New Drug Reviews

Antiplatelet

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Brilinta*[™].

Antiinfective

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Dificid*[™].

Antidepressant

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Viibryd*[™].

Antineoplastics

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Xalkori*[™] and *Zelboraf*[™].

Anticoagulants

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Xarelto*[™].

Supplemental Rebate Class Reviews

All supplemental rebate classes were reviewed, but only the drugs with a recommendation for change in PDL status are highlighted below. The recommendations on all other supplemental rebate drugs remained the same as the current PDL status, which is located at http://dch.georgia.gov/00/channel_title/0,2094,31446711_32050640,00.html.

Androgens/Anabolics

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Androgel*[®] 1.62%.

Anticoagulants

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Arixtra*[®].

Antihyperkinesia

The DUR Board recommended no changes at this time and to reevaluate the class in 6 months.

Asthma and Bronchodilator Agents

The DUR Board recommended *Non-Preferred* status for *Theophylline Elixir*.

Contraceptives

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Drosperinone-Containing Products* (*Beyaz*[®], *Gianvi*[®], *Loryna*[®], *Ocella*[®], *Safryal*[®], *Syeda*[®], *Yasmin*[®], *Yaz*[®], *Zarah*[®]) and for *Ortho Evra*[®].

Diabetic – Non-Insulin Injectables

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Victoza*[®].

Direct Renin Inhibitors and Combinations

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Aliskiren-Containing Products* (*Amturnide*[®], *Tekamlo*[®], *Tekturna*[®], *Tekturna*[®] HCT and *Valturna*[®]).

Growth Hormones

The DUR Board recommended Goold Health Systems request a best and final offer from the manufacturers and to reevaluate the class at the June 21, 2012 meeting.

Hepatitis C

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Victrelis*[®].

Insulins/Insulin Pens

The DUR Board recommended *Preferred* status for *Humalog*[®] vials, *Humalog*[®] Mix 75/25 vials and *Humulin*[®] 70/30 vials.

Nasal Steroids

The DUR Board recommended *Preferred* status for *Nasacort*[®] AQ.

Ophthalmic Quinolones

The DUR Board recommended *Preferred* status for *Moxeza*[®].

Phosphate Binders

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Eliphos*[®] and *Non-Preferred* status with *Prior Authorization* for *PhosLo*[®].